- Home
- » Tags
- » Peginesatide
Top View
- KDIGO Clinical Practice Guideline for Anemia in Chronic Kidney Disease
- NIOSH Hazardous Drugs Table 1 Antineoplastic Drugs
- NON-ONCOLOGY N = 1919 Distinct NDC N = 244 Distinct Generic
- Erythropoiesis Stimulating Agents: Approaches to Modulate Activity
- OMONTYS (Peginesatide) Injection, Dosage Form Strengths for Intravenous Or Subcutaneous Use Single Use Vials 2 Mg/0.5 Ml, 3 Mg/0.5 Ml, Initial U.S
- Clinical Pharmacology Biopharmaceutics Review(S)
- Erythropoiesis-Stimulating Agents
- Dose-Finding Study of Peginesatide for Anemia Correction in Chronic Kidney Disease Patients Article
- Omontys, INN-Peginesatide
- SAFE HANDLING of HAZARDOUS DRUGS Updated 5/22/2020
- Custodians of Medicaid Services Manual From
- Article Peginesatide for Maintenance Treatment of Anemia In
- 2. the Case for Protein Pegylation
- Amgen 2011 Annual Report and Financial Summary
- Profile of Peginesatide and Its Potential for the Treatment of Anemia in Adults with Chronic Kidney Disease Who Are on Dialysis
- Alaska Medicaid Preferred Drug List (PDL)
- Allergen Extracts Prior Authorization Guidelines
- Scientific and Regulatory Reasons for Delay and Denial of FDA Approval of Initial Applications for New Drugs, 2000-2012
- Erythropoiesis Stimulating Agents (Esas) When It Is Determined to Be Medically Necessary Because the Medical Criteria and Guidelines Noted Below Are Met
- November 1, 2012 RISK-BENEFIT ASSESSMENT in a COHORT OF
- Specialty Drug List
- Drug Products with Medication Guides Joseph A
- [2016]. NIOSH List of Antineoplastic and Other Hazardous Drugs in Healthcare Settings, 2016
- Clinical Implications of Molecular Pegylation on Therapeutic Proteins
- An Open-Label, Sequential, Dose-Finding Study of Peginesatide
- WHO EML 2016-2017 - Erythropoietin-Stimulating Agents December 2016
- The Use of Stems in the Selection of International Nonproprietary Names (INN) for Pharmaceutical Substances
- Standard Specialty PA and QL List October 2014
- ( 12 ) United States Patent
- New Drugs 2012, the Second Half
- The Pharmaceutical Industry in 2018. an Analysis of FDA Drug Approvals from the Perspective of Molecules
- Rhepo for the Treatment of Erythropoietin Resistant Anemia in Hemodialysis Patients – Risks and Benefits
- Lessons Learned from Peginesatide in the Treatment of Anemia Associated with Chronic Kidney Disease in Patients on Dialysis
- Blue Cross Medicare Advantage Specialty Pharmacy Code List